Chris holds a BSc and PhD in Biochemistry from the University of Bristol, UK. Following post-doctoral work, he spent several years at Roussel-UCLAF and Hoechst Marion Roussel before joining Ferring Pharmaceuticals. Chris led the Biology group and was responsible for transition of candidates into development. In 2008, Chris co-led the spin-out of Vantia Ltd and most recently was Chief Operating Officer where he was responsible for development activities through Phase 3 trials.In his position as Chief Development Officer, Chris is responsible for all development-related activities within KalVista Pharmaceuticals.
Organization Name | Title At Company | Start Date | End Date | |
---|---|---|---|---|
KalVista Pharmaceuticals | Chief Development Officer | — | — | Detail |